J Cancer 2020; 11(21):6248-6255. doi:10.7150/jca.47106

Research Paper

IL36 indicating good prognosis in human Hepatocellular Carcinoma

Miao Hu1#, Ying Tong2#, Haisheng Fang3#, Jie Tang1, Lang Liu4, Yanni Hu1, Jingze Li4, Lan Zhong1✉

1. Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, No.150 Jimo Road, Pudong New Area, Shanghai, China.
2. Clinical Laboratory, Cancer Hospital of Fudan University, Fudan University, Shanghai, China, No 270 Dong 'an road, Shanghai, China.
3. Department of pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China, No 300 Guangzhou road, Nanjing, China.
4. Center of Digestive Endoscopy, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, No.150 Jimo Road, Pudong New Area, Shanghai, China.
#Co-first authors with equal contributions to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Hu M, Tong Y, Fang H, Tang J, Liu L, Hu Y, Li J, Zhong L. IL36 indicating good prognosis in human Hepatocellular Carcinoma. J Cancer 2020; 11(21):6248-6255. doi:10.7150/jca.47106. Available from http://www.jcancer.org/v11p6248.htm

File import instruction

Abstract

Background and Aim: Hepatocellular carcinoma (HCC) is the leading cause of cancer death in men before the age of 60 years in China. Interleukin (IL)36 played important roles in antitumor immune responses, but its role in HCC is still unknown. We aimed to explore the correlation between IL36 and prognosis of HCC patients.

Methods: The expression of IL36 was measured by Immunohistochemistry (IHC), serum Enzyme-linked Immunosorbent Assay (ELISA) and flow cytometry (FCM). Chi-square test was performed to analyze the relationship between IL36 expression and clinical parameters of HCC patients. The correlation between IL36 expression and prognosis of HCC patients was evaluated by Kaplan-Meier method and Cox regression analysis.

Results: The IL36 expression in HCC tumor samples was lower than that in paired peri-tumor samples; the analyses suggested that there was no correlation between IL36 expression and age, gender, and tumor size, but tight relationship between IL36 expression and liver cirrhosis, metastasis and some other clinical parameters. The results of Kaplan-Meier analysis indicated positive expression of IL36 could induce high survival rate of patients. The detection of IL36 with ELISA suggested that expression of IL36 in serum was the highest in patients of HCC, other than the chronic hepatitis patients and the healthy. The result of FCM suggested the expression of IL36 was higher in CD4+ T cells than other immune cells.

Conclusions: There is a close relationship between the expression of IL36 and the prognosis of HCC, higher expression of IL36 suggested better prognosis and longer survival of HCC.

Keywords: Hepatocellular carcinoma (HCC), biomarker, interleukin 36 (IL36), prognosis